Objectives: To investigate the relationships between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis (AS) and the impact of 12 weeks' etanercept treatment versus sulfasalazine or placebo. Methods: Data were combined from four clinical trials for patients with AS who received at least one dose of etanercept, sulfasalazine or placebo and had at least one postbaseline assessment value. Linear regression was performed (controlling for site, protocol and demographics), to explore the relationship between inflammation (C-reactive protein [CRP]), nocturnal back pain (visual analog scale [VAS] 0-100 mm) and fatigue (VAS 0-100 mm Bath AS Disease Activity Index fatigue item). Results: Out of 1283 patients (etanercept, n ¼ 867; sulfasalazine, n ¼ 187; placebo, n ¼ 229), improvement in nocturnal back pain was a significant predictor of improvement in fatigue. Significant correlations were found between nocturnal back pain and fatigue, but not CRP levels. Etanercept provided significantly greater pain/fatigue improvement than sulfasalazine or placebo. Improvements in nocturnal back pain and fatigue had weak relationships with improvement in inflammation (CRP level).
Introduction
Ankylosing spondylitis (AS) is characterized by inflammation of the sacroiliac joints and spine, with nocturnal back pain and fatigue being chief complaints; AS is associated with impaired functioning and reduced healthrelated quality of life. 1, 2 Nocturnal back pain is a primary symptom of AS, with 62-63% of patients also experiencing severe fatigue. 3, 4 At the cellular level, measurements of inflammation biomarkers such as C-reactive protein (CRP) are used in diagnosis and are components of outcome assessments and predictors of treatment response. [5] [6] [7] Relationships between inflammation, back pain and fatigue have not been well established.
The AS Disease Activity Score (ASDAS) utilizes both back pain and CRP in its algorithm to help assess the overall AS disease state at any given timepoint. 8 Independently, back pain and CRP levels at the start of treatment are strongly correlated with improvement in treatment response (ASDAS) and a 20% improvement in the Assessments of the SpondyloArthritis International Society criteria (ASAS). 9, 10 In addition, CRP level at the start of treatment has been strongly associated with a 50% improvement in the Bath AS Disease Activity Index (BASDAI), of which back pain is a component. 11 Elevated CRP levels at baseline have been associated with an effective response to anti-tumor necrosis factor (TNF) therapy, achievement of remission by various functional and disability component indices and continuation of therapy. [5] [6] [7] As an independent variable, fatigue has been under-studied in AS; it has mainly been researched as an item of composite measures such as the BASDAI. 4, 5 The aetiology of fatigue in AS remains elusive, yet a number of studies have shown that nocturnal back pain and disease activity are strongly related to fatigue in patients with AS. 3, 4, [12] [13] [14] [15] Despite these findings, fatigue continues to be routinely overlooked in clinical practice as a treatable AS symptom, even though it has been reported as the third most common complaint. 4, 14 Although CRP, back pain and fatigue are used independently and as variables in composite measures to assess AS disease state and treatment efficacy, the relationship between CRP and back pain has not been well characterized.
Nonsteroidal anti-inflammatory drug (NSAID) therapy is the first-line treatment for AS and reports are varied regarding its effect on pain and fatigue. Patients have reported that NSAID therapy has alleviated their fatigue symptoms, but that it had a greater effect on pain and functional impairment than on fatigue. 1, 16 Disease-modifying anti-rheumatic drugs are other conventional treatments that may be associated with greater improvements in fatigue compared with other traditional therapies, although their effect on pain is variable and largely ineffective in those with axial disease. 14, 17 Biologic therapies, such as the fully-human TNF-soluble receptor, etanercept, tend to be more effective in improving the signs and symptoms of AS (including inflammation, nocturnal back pain and fatigue) in controlled studies. [18] [19] [20] [21] [22] In this novel analysis, using data derived from several controlled clinical trials of etanercept in patients with active AS, relationships between inflammation (measured by CRP levels), nocturnal back pain and fatigue were investigated, and the impact of 12 weeks' etanercept treatment was evaluated. Understanding these relationships may help clinicians in making evidence-based decisions and maximize treatment benefits for patients with AS.
Patients and methods

Study population and design
Data were pooled from four published, multicentre, double-blind, randomized, placebo-controlled trials conducted in Asia, Australia, Canada, Europe, Latin America, the Middle East and the USA, in which adult patients (aged ! 18 years) with active AS were treated with etanercept, sulfasalazine or placebo (Table 1) . 18, 20, 23, 24 Patients were diagnosed with AS according to the modified New York criteria. 25 Those who received at least one dose of etanercept (50 mg or 25 mg weekly), sulfasalazine (1.5 g twice a day) or placebo and had at least one postbaseline assessment were included in the analyses. Patients in the four studies were recruited between March 2002 and January 2008. Details regarding specific inclusion/exclusion criteria, treatment allocation and randomization for all four studies have been reported elsewhere. 18, 20, 23, 24 The study designs were qualitatively consistent across trials. A week-12 endpoint was selected for the pooled analysis as it was shared by all four trials. Data for the etanercept 50-mg weekly and 25-mg twiceweekly dosing groups were combined to create one etanercept treatment group for analysis.
These four studies had been conducted in compliance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guidelines and all applicable local/country specific regulations. Before the start of each study, independent ethics committees or institutional review boards in each country reviewed and approved each study, and written informed consent was received from all participants.
Symptom assessment
Nocturnal back pain was assessed using a single-item visual analog scale (VAS), with scores ranging from 0-100 mm, where 0 mm represented no pain and 100 mm represented worst possible pain. Fatigue was assessed using the fatigue item of the BASDAI, with scores ranging from 0-100 mm on a VAS (0 mm represented no fatigue; 100 mm represented the worst possible symptoms of fatigue). 26 CRP levels were assessed as an objective measure of inflammation using the standard procedures of centralized laboratories for each clinical trial. The presence of the human leukocyte antigen (HLA)-B27 allele is strongly associated with a diagnosis of AS and was assessed using the standard procedures of centralized laboratories (polymerase chain reaction) for each clinical trial. Nocturnal back pain, fatigue and CRP levels were assessed at baseline and at week 12.
Statistical analyses
Descriptive statistics and the correlations (Pearson's correlation coefficient) between variables were calculated for baseline, week 12 and change from baseline to week 12. Linear regression was performed, controlling for pooled site, protocol and demographic characteristics (i.e., age, sex and disease duration), to explore the relationship 
Results
In total, 1283 patients (etanercept, n ¼ 867; sulfasalazine, n ¼ 187; placebo, n ¼ 229) were included in this 12-week analysis. No significant differences in baseline demographics or disease characteristics between treatment groups were found ( (11) years and mean (standard deviation [SD]) disease duration was 9 (9) years. The mean BASDAI score was 60 mm at baseline; mean nocturnal back pain and fatigue scores were 62 mm and 61 mm, respectively, indicating severe pain and fatigue (defined as ! 50 mm) at baseline. Overall, 83% were positive for the HLA-B27 allele. Significant correlations were found between nocturnal back pain and fatigue ( Figure 1 ; Table 3 ). Patient-reported nocturnal back pain at baseline was moderately correlated with fatigue at baseline (r ¼ 0.40; P < 0.0001). Nocturnal back pain and fatigue VAS scores at week 12 were more strongly correlated (r ¼ 0.79; P < 0.0001). Changes from baseline for the two variables also were strongly correlated (r ¼ 0.61; P < 0.0001). Linear regression showed that, even after controlling for patient age, sex and disease duration, improvement in nocturnal back pain was a significant predictor of improvement in fatigue (estimate, 0.49; P < 0.0001). Significant but weak correlations were observed between inflammation and 
Statistical significance
Nocturnal back pain at baseline 0.40 P < 0.0001 0.18 P < 0.0001 À0.13 P < 0.0001 Nocturnal back pain at week 12 0.28 P < 0.0001 0.79 P < 0.0001 0.57 P < 0.0001 Nocturnal back pain change from baseline À0.03 P ¼ 0.2346 0.58 P < 0.0001 0.61 P < 0.0001 nocturnal back pain and fatigue. Correlations between change from baseline in CRP levels and changes from baseline in nocturnal back pain and fatigue were r ¼ 0.19 (P < 0.0001) and r ¼ 0.18 (P < 0.0001), respectively (Table 4) .
Etanercept provided significantly greater improvements from baseline to week 12 in pain and fatigue than either sulfasalazine or placebo (Figure 2 ). Nocturnal back pain was improved by 58% in the etanercept group, compared with 38% and 16% in the sulfasalazine and placebo groups, respectively (P < 0.0001); this represented a mean change from baseline of À36.2, À23.8 and À9.4, respectively. Fatigue significantly improved in the etanercept group, by 45%, compared with 26% and 13% of the sulfasalazine and placebo groups, respectively (P < 0.0001); this represented a mean change from baseline of À27.5, À15.4 and À8.0, respectively. Improvement in fatigue in the etanercept group was significant after controlling for change in nocturnal back pain, but was not significant in the sulfasalazine group.
Discussion
Fatigue is a major common symptom experienced by the majority of patients with AS; this burden of disease leads to a significantly larger impact on their lives than in the general population. 1, 13, 27, 28 Fatigue has been shown to be severe (BASDAI fatigue item !50 mm) in 62-63% of patients with AS and has been reported as the third most common symptom after pain and stiffness. 3, 16 Data presented in the current study, from a pooled population of patients with AS, show nocturnal back pain -one of the major symptoms of AS -to be strongly correlated with fatigue. This is most likely because of nocturnal pain disrupting restorative and high-quality sleep, thus contributing to the severity of fatigue during waking hours. In the current study, improvement in nocturnal back pain with treatment was associated with reduced fatigue. Improvements in both nocturnal back pain and fatigue were shown to have weak, yet statistically significant, relationships with improvement in inflammation, most likely revealed by the large sample size in the current study. These results complement other findings of weak relationships between fatigue and inflammation and between back pain and inflammation in patients with AS. 3, 16, 29 Etanercept was shown to be superior to sulfasalazine in reducing nocturnal back pain and this finding was mirrored by a similar decrease in fatigue. In addition, etanercept provided improvement in fatigue, even after controlling for its effects on nocturnal back pain.
This post hoc analysis was limited in utilizing only one question/measure of fatigue (from the BASDAI scale), which may not have provided the full extent and details of the patients' fatigue. 26 In addition, the short observation period prevented any long-term analysis of changes in fatigue. The original studies from which the data for this study were drawn were not intended to evaluate the impact of AS on the effects of fatigue on mood and family interactions. Sleep studies, hygiene and logs were not collected, nor were other mitigating factors addressed (such as level of education, consumption of caffeine-containing drinks and work [shift work/night work or manual labour]). Additional studies are warranted to more comprehensively assess the aetiology and consequences of fatigue in patients with AS. Although studies have reported relationships between various patient-reported measures and fatigue, we believe this is the first analysis that has shown nocturnal back pain to be predictive of fatigue in this population of patients with AS. Patients treated with etanercept demonstrated a superior improvement in both nocturnal back pain and fatigue compared with sulfasalazine and placebo. Laboratory measures of disease inflammation (CRP levels) were not related to changes in nocturnal back pain or fatigue, indicating that clinicians should not rely solely on CRP levels to assess disease activity. Attention should also be focused on the patient's report of nocturnal back pain, especially given its link to fatigue and the possible subsequent effects on daily life.
Declaration of conflicting interest
Potential conflicts of interest include the following: M Hammoudeh is a clinical investigator of ankylosing spondylitis clinical trials sponsored by Pfizer Inc; DJ Zack is a former employee of Amgen; VM Stewart and AS Koenig are current employees of Pfizer Inc; Previously, W Li was an employee of PharmaNet/i3, who were paid SSZ] 1.5 g orally twice daily; placebo twice weekly). P < 0.0001 for all between-group comparisons at week 12 for both pain and fatigue (one-way analysis of variance with treatment as a factor).
contractors to Pfizer Inc in the development of this manuscript. All authors participated in the development of this report and approved the final content for publication.
